[vc_row][vc_column][vc_empty_space height=”40px”][vc_column_text css_animation=”slideInLeft” css=””]

Giant Cell Arteritis (GCA) is a chronic inflammatory disease affecting large and medium-sized arteries, particularly the temporal arteries, often seen in adults over 50. Major symptoms include new-onset headache, scalp tenderness, jaw claudication, vision disturbances, and fatigue. If untreated, it can lead to serious complications such as permanent vision loss or stroke.

The Janus kinase (JAK) pathway is involved in GCA by transmitting pro-inflammatory cytokine signals, including IL-6, IL-12, and IFN-γ, which drive vascular inflammation. Upadacitinib is the first and only once-daily, non-steroidal oral medication approved for treating Giant Cell Arteritis (GCA). In clinical trials, Upadacitinib helped more patients with GCA reach remission compared to those treated with steroids alone.

[/vc_column_text][vc_empty_space height=”70px”][/vc_column][/vc_row][vc_row type=”vc_default” bg_type=”image” parallax_style=”vcpb-default” bg_image_new=”id^368|url^https://upajak.com/wp-content/uploads/2025/05/bg22-scaled.jpg|caption^null|alt^null|title^bg22|description^null” bg_image_repeat=”no-repeat” bg_img_attach=”fixed” bg_override=”ex-full”][vc_column][vc_empty_space height=”200px”][/vc_column][vc_column width=”1/3″][vc_column_text css_animation=”slideInRight” css=”” el_class=”section-img-title”]Upadacitinib offers —[/vc_column_text][/vc_column][vc_column width=”2/3″][/vc_column][vc_column][vc_empty_space height=”200px”][/vc_column][/vc_row][vc_row type=”vc_default” css_animation=”slideInUp”][vc_column width=”1/6″][/vc_column][vc_column width=”2/3″][vc_column_text css=””]

[/vc_column_text][vc_empty_space height=”70px”][/vc_column][vc_column width=”1/6″][/vc_column][/vc_row][vc_row type=”vc_default” el_class=”box-sha”][vc_column width=”1/6″][/vc_column][vc_column width=”2/3″][vc_empty_space height=”20px”][vc_column_text css=”” el_class=”title-bg”]

Most people on Upadacitinib were steroid-free 2 times quicker

[/vc_column_text][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”4/5″][vc_single_image image=”513″ img_size=”full” alignment=”center” css=””][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/6″][/vc_column][vc_column][vc_empty_space height=”60px”][/vc_column][/vc_row][vc_row type=”vc_default” el_class=”box-sha”][vc_column width=”1/6″][/vc_column][vc_column width=”2/3″][vc_row_inner][vc_column_inner][vc_column_text css=”” el_class=”title-bg”]

More people on Upadacitinib + 6-month steroid taper stayed in remission from
3 months to 1 year

[/vc_column_text][/vc_column_inner][/vc_row_inner][vc_row_inner][vc_column_inner width=”1/6″][/vc_column_inner][vc_column_inner width=”2/3″][vc_single_image image=”514″ img_size=”full” alignment=”center” css=””][/vc_column_inner][vc_column_inner width=”1/6″][/vc_column_inner][/vc_row_inner][/vc_column][vc_column width=”1/6″][/vc_column][vc_column][vc_empty_space height=”60px”][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]

[/vc_column_text][/vc_column][/vc_row]